A versatile genomic transgenesis platform with enhanced λ integrase for human Expi293F cells
0303 health sciences
Science
human cell line engineering
Site-Specific Integration; Cassette Exchange Rmce; Lentiviral Vectors; Cho-Cells; Lines; Dna; Activation
Bioengineering and Biotechnology
Expi293F Cells
Expi293F cells
3. Good health
λ integrase
03 medical and health sciences
Human Cell Line Engineering
site-specific transgenesis
Biotherapeutics
Site-Specific Transgenesis
microencapsulation
λ Integrase
biotherapeutics
Microencapsulation
TP248.13-248.65
Biotechnology
DOI:
10.3389/fbioe.2023.1198465
Publication Date:
2023-06-24T09:49:26Z
AUTHORS (9)
ABSTRACT
Reliable cell-based platforms to test and/or produce biologics in a sustainable manner are important for the biotech industry. Utilizing enhanced λ integrase, a sequence-specific DNA recombinase, we developed a novel transgenesis platform involving a fully characterized single genomic locus as an artificial landing pad for transgene insertion in human Expi293F cells. Importantly, transgene instability and variation in expression were not observed in the absence of selection pressure, thus enabling reliable long-term biotherapeutics testing or production. The artificial landing pad for λ integrase can be targeted with multi-transgene constructs and offers future modularity involving additional genome manipulation tools to generate sequential or nearly seamless insertions. We demonstrated broad utility with expression constructs for anti PD-1 monoclonal antibodies and showed that the orientation of heavy and light chain transcription units profoundly affected antibody expression levels. In addition, we demonstrated encapsulation of our PD-1 platform cells into bio-compatible mini-bioreactors and the continued secretion of antibodies, thus providing a basis for future cell-based applications for more effective and affordable therapies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (52)
CITATIONS (1)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....